TAGLN3

Across TCGA pan-cancer cohorts, TAGLN3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TAGLN3 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TAGLN3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TAGLN3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where TAGLN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.975	0.492	.002	14	view →
LUAD	OS	Median	II,III,IV	0.325	0.915	.006	12	view →
CCRCC	DFS	Quartile	II,III,IV	0.448	0.828	.017	7	view →
GBM	DFS	Tertile	All	0.831	0.677	.034	5	view →
HNSC	DFS	Median	All	0.602	0.946	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TAGLN3–PDAC (DFS)

Open the PDAC breakdown →